Pipeline & Proof of Concept

Our robust and growing pipeline has the potential to play a critically influential role in the practice of Gut Microbiome Medicine and create significant value for patients and shareholders.

Dr. Eugene Chang’s NIH-funded lab, the Chang Lab at the University of Chicago in collaboration with The University of Chicago Duchossois Family Institute produced the GB diagnostic technology platform.

Therapeutic area

Functional Health

IBS

Functional Health

IBD

Indication

POC*

DISCOVERY & IDEATION

INVENTION & PROTOTYPING

PRECLINICAL

CLINICAL

Regulatory Decision

Adults (ages 18-64)

Irritable Bowel Syndrome (IBS)

GB-0001

GB-0001

Early Childhood Development (0-5)

Older Adult Longevity (ages 65+)

GB-00XX

GB-00XX

IBD Patients Mangement/
Biological Therapy

GB-00XX

Unmet need and thought leadership:

CS Therapeutic Platform Technology Pipeline:

Therapeutic area

Infectious Diseases

Oncology

Military

Indication

POC*

DISCOVERY

PRECLINICAL

Phase I

Phase II

Phase III

GI - Surgical Site Infection
 (Anastomotic Leak)

Surgical Site Infection

Sepsis

Wound Site Virulence Suppression

CS-0003

CS-0003

CS-00XX

CS-00XX

Colon Cancer Recurrence

Chemotherapy Related Toxicities
and Infections

CS-00XX

CS-00XX

Total Body Irradiation

Army Relevant Pathogens/TD
/AMR Colonization

CS-00XX

CS-00XX

The study is in progress.

Highlighted Proof of Concept Publications Below:

Anastomotic Leak

SSI via Trojan Horse Mechanism

Sepsis

Colon Cancer Recurrence

Thought Leadership